Pros
The company still holds tremendous resources that it can apply -- if it can finally commit to a single vision for the future. The stock price is flat and has been that way despite products being launched and others recalled -- in this economy a flat stock price is pretty good. People like to knock Kindler (CEO) -- apparently there are thousands that believe they can do a better job -- but I think he has his hands tied by an underachieving board (and that's what needs change).
Cons
Change...change...change. The ink has not dried on one reorganization when another is already announced. The board is not laying out a consistent vision for the future of the company and enabling senior leaders to execute. It gets tiring listening to "old timers" complain about how the old Pfizer used to be so much better.
